brightpoint

Jefferies & Company has upgraded the following companies: Brightpoint (NASDAQ: CELL) from Hold to Buy Omega Healthcare Investors (NYSE: OHI) from Hold to Buy, PT raised from $22 to $24 Sabra Health Care (NASDAQ: SBRA) from Hold to Buy, PT raised from $18 to $19

Jefferies & Company has upgraded Brightpoint (NASDAQ: CELL) from Hold to buy and has established a $12.50 price target.

A recent report by Jefferies previews some of the top telecom and wireless equipment companies, including: Motorola (NYSE: MMI), Research in Motion (NASDAQ: RIMM), Dragonwave (NASDAQ: DRWI), and Brightpoint (NASDAQ: DRWI). Motorola will report first quarter earnings on April 28th and are expecting...

Citi is out with its report on Brightpoint (NASDAQ: CELL), downgrading shares of CELL from Buy to Hold. In a note to clients, Citi writes, "We are downgrading Brightpoint shares from Buy to Hold & reducing our target from to $11 from $17.50 both on lower estimates & lower valuation...

In its Q410 preview of Brightpoint, Inc. (NASDAQ: CELL), Credit Suisse said that it expects “results to be in-line to slightly better than our estimates, given broad based handset market strength.” “We forecast revenue of $1.03bn (+16% qoq), clean OMs of 2.8% (+40bp qoq), and PF EPS of $0.28 versus...

While strong demand is clearly encouraging, Citigroup said that it believes supply tightness could limit handset industry unit upside in 4Q. This could have a negative impact on Brightpoint, Inc. (NASDAQ: CELL). “However, continued strong demand coupled with supply tightness and the secular shift...

Brightpoint, Inc. (NASDAQ: CELL) delivered a strong September quarter, easily topping Street expectations, Oppenheimer reports. “We believe building momentum in Europe post restructuring, a recovery in the pre-paid market in the US, and mgmt's ability to add new business in Singapore all helped...

Oppenheimer has published a research report on Brightpoint, Inc. (NASDAQ: CELL) after the company reported a strong September quarter that topped Street expectations with ease. In the report, Oppenheimer writes "Brightpoint delivered a strong Sept. qtr., easily topping Street expectations. We...